DDInter1340 DDInter1152
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha. Cytochrome P450 2C19, Cytochrome P450 2C8, Cytochrome P450 2C9, Cytochrome P450 2B6, Cytochrome P450 1A2, and Cytochrome P450 2D6 are known to metabolize mephenytoin. Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. Mephenytoin and oxazolidinedione derivatives are associated with higher incidences of blood dyscrasias compared to other anticonvulsants.
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mephenytoin
Omeprazole {u} (Compound) binds {v} (Gene) CYP2C18
CYP2C18 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mephenytoin
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mephenytoin
Omeprazole {u} (Compound) binds {v} (Gene) CYP2C18
CYP2C18 {u} (Gene) is bound by {v} (Compound) Diphenhydramine
Diphenhydramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mephenytoin
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mephenytoin
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osilodrostat
Osilodrostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mephenytoin
Omeprazole {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dronabinol
Dronabinol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mephenytoin
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mephenytoin
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may lead to a major life threatening interaction when taken with {v} Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mephenytoin
Omeprazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mephenytoin
Omeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Mephenytoin
Omeprazole (Compound) binds CYP2C18 (Gene) and CYP2C18 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Mephenytoin
Omeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Mephenytoin
Omeprazole (Compound) binds CYP2C18 (Gene) and CYP2C18 (Gene) is bound by Diphenhydramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Omeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Omeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Omeprazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Omeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Omeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Omeprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Mephenytoin